WallStreetZenWallStreetZen

NASDAQ: QURE
Uniqure Nv Stock

Open Broker Account
$25.65-0.38 (-1.46%)
Updated Dec 5, 2022
QURE Price
$25.65
Fair Value Price
$35.06
Market Cap
$1.20B
52 Week Low
$12.52
52 Week High
$30.41
P/E
-9.54x
P/B
2.85x
P/S
14.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$61.43M
Earnings
-$125.39M
Gross Margin
94.3%
Operating Margin
-189.84%
Profit Margin
-204.1%
Debt to Equity
0.52
Operating Cash Flow
-$137M
Beta
1.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

QURE Overview

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how QURE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

QURE ($25.65) is undervalued by 26.85% relative to our estimate of its Fair Value price of $35.06 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
QURE ($25.65) is significantly undervalued by 26.85% relative to our estimate of its Fair Value price of $35.06 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
QURE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QURE due diligence checks available for Premium users.

Be the first to know about important QURE news, forecast changes, insider trades & much more!

QURE News

Valuation

QURE fair value

Fair Value of QURE stock based on Discounted Cash Flow (DCF)
Price
$25.65
Fair Value
$35.06
Undervalued by
26.85%
QURE ($25.65) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QURE ($25.65) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QURE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

QURE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-9.54x
Industry
14.34x
Market
21.63x

QURE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.85x
Industry
4.96x
QURE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

QURE's financial health

Profit margin

Revenue
$1.4M
Net Income
-$47.9M
Profit Margin
-3,302.8%
QURE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
QURE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$638.2M
Liabilities
$217.1M
Debt to equity
0.52
QURE's short-term assets ($464.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QURE's short-term assets ($464.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QURE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
QURE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$49.0M
Investing
-$5.1M
Financing
$301.0k
QURE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

QURE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
QURE$1.20B-1.46%-9.54x2.85x
IMGN$1.20B-0.73%-6.62x6.73x
IMGO$1.21B+0.36%-28.69x7.03x
MNKD$1.21B-4.36%-12.13x-5.10x
TGTX$1.19B-6.96%-4.61x11.80x

Uniqure Nv Stock FAQ

What is Uniqure Nv's quote symbol?

NASDAQ: QURE) Uniqure Nv trades on the NASDAQ under the ticker symbol QURE. Uniqure Nv stock quotes can also be displayed as NASDAQ: QURE.

If you're new to stock investing, here's how to buy Uniqure Nv stock.

What is the 52 week high and low for Uniqure Nv (NASDAQ: QURE)?

(NASDAQ: QURE) Uniqure Nv's 52-week high was $30.41, and its 52-week low was $12.52. It is currently -15.65% from its 52-week high and 104.87% from its 52-week low.

How much is Uniqure Nv stock worth today?

(NASDAQ: QURE) Uniqure Nv currently has 46,815,109 outstanding shares. With Uniqure Nv stock trading at $25.65 per share, the total value of Uniqure Nv stock (market capitalization) is $1.20B.

Uniqure Nv stock was originally listed at a price of $14.61 in Feb 5, 2014. If you had invested in Uniqure Nv stock at $14.61, your return over the last 8 years would have been 75.56%, for an annualized return of 7.29% (not including any dividends or dividend reinvestments).

How much is Uniqure Nv's stock price per share?

(NASDAQ: QURE) Uniqure Nv stock price per share is $25.65 today (as of Dec 5, 2022).

What is Uniqure Nv's Market Cap?

(NASDAQ: QURE) Uniqure Nv's market cap is $1.20B, as of Dec 6, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Uniqure Nv's market cap is calculated by multiplying QURE's current stock price of $25.65 by QURE's total outstanding shares of 46,815,109.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.